3/24
07:53 am
pvla
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 [TheStreet.com]
Medium
Report
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 [TheStreet.com]
3/24
07:30 am
pvla
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
Medium
Report
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
3/23
07:40 am
pvla
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services [Yahoo! Finance]
Low
Report
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services [Yahoo! Finance]
3/23
07:30 am
pvla
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Low
Report
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
3/17
12:32 am
pvla
Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market [Seeking Alpha]
Medium
Report
Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market [Seeking Alpha]
3/16
03:21 pm
pvla
Palvella Therapeutics (PVLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $210.00 price target on the stock.
Low
Report
Palvella Therapeutics (PVLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $210.00 price target on the stock.
3/16
07:41 am
pvla
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin [Yahoo! Finance]
Low
Report
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin [Yahoo! Finance]
3/16
07:30 am
pvla
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Medium
Report
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
3/10
08:04 am
pvla
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations [Yahoo! Finance]
Low
Report
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations [Yahoo! Finance]
3/10
07:30 am
pvla
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
Medium
Report
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
3/2
07:30 am
pvla
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Low
Report
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
2/25
07:57 pm
pvla
Palvella Therapeutics Announces Pricing of Upsized Public Offering
High
Report
Palvella Therapeutics Announces Pricing of Upsized Public Offering
2/25
12:27 pm
pvla
Palvella Therapeutics (PVLA) had its price target raised by Mizuho from $205.00 to $250.00. They now have an "outperform" rating on the stock.
Medium
Report
Palvella Therapeutics (PVLA) had its price target raised by Mizuho from $205.00 to $250.00. They now have an "outperform" rating on the stock.
2/25
08:03 am
pvla
Palvella Therapeutics (PVLA) had its price target raised by BTIG Research from $192.00 to $215.00. They now have a "buy" rating on the stock.
Medium
Report
Palvella Therapeutics (PVLA) had its price target raised by BTIG Research from $192.00 to $215.00. They now have a "buy" rating on the stock.
2/24
05:02 pm
pvla
Palvella Therapeutics (PVLA) was given a new $210.00 price target by Truist Financial Corporation.
Medium
Report
Palvella Therapeutics (PVLA) was given a new $210.00 price target by Truist Financial Corporation.
2/24
04:05 pm
pvla
Palvella Therapeutics Announces Proposed Public Offering
Medium
Report
Palvella Therapeutics Announces Proposed Public Offering
2/24
02:40 pm
pvla
Palvella Therapeutics (PVLA) had its price target raised by Chardan Capital from $174.00 to $210.00. They now have a "buy" rating on the stock.
Low
Report
Palvella Therapeutics (PVLA) had its price target raised by Chardan Capital from $174.00 to $210.00. They now have a "buy" rating on the stock.
2/24
01:14 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $250.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $250.00 price target on by analysts at Stifel Nicolaus.
2/24
11:06 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/24
06:30 am
pvla
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
High
Report
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
2/23
05:34 pm
pvla
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations [Yahoo! Finance]
High
Report
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations [Yahoo! Finance]
2/23
05:00 pm
pvla
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
High
Report
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
2/2
10:08 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/2
08:24 am
pvla
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Low
Report
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
2/2
07:30 am
pvla
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Medium
Report
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis